Case Report

Drug-Induced Liver Injury Caused by the Histrelin (Vantus®) Subcutaneous Implant

Authors: Jonathan M. Ricker, DO, William F. Foody, MD, Nathan M. Shumway, DO, Janet C. Shaw, MD

Abstract

Drug-induced liver injury (DILI) is the leading cause of acute hepatic failure in the United States. Up to 13% of acute liver failure cases occur due to drugs other than acetaminophen. This clinical diagnosis, made after other causes of liver injury have been excluded, requires establishing a causal relationship between drug exposure and liver injury. The case of a patient with liver injury following a subcutaneous histrelin (Vantus®) implant as therapy for advanced prostate cancer is presented.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003;217–226.
 
2. Ostapowicz G, Fontana RJ, Schiodt SV, et al; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary centers in the United States. Ann Intern Med 2002;137:947–954.
 
3. Lee WM, Squires RH Jr, Nyberg SL, et al. Acute liver failure: summary of a workshop. Hepatology 2008;47:1401–1415.
 
4. Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005;33:155–164.
 
5. Vantus® (Histrelin Implant) [Package Insert.] Lexington, MA, Indevus Pharmaceuticals, Inc., 2008.
 
6. Gunnet JQ, Demarest KT, Hahn DW, et al. Effects of sustained release formulation of the gonadotropin-releasing hormone agonist and oestradiol, and ovarian LH/human chorionic gonadotropin receptor content in rats. J Endocrinol 1991;131:211–218.
 
7. Hahn DW, Carraher RP, Foldesy RG, et al. Development of an animal model for quantitatively evaluating effects of drugs on endometriosis. Fertil Steril 1985;44:410–415.
 
8. Spitz IM, Chertin B, Lindenberg T, et al. Long acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer. N Engl J Med 1999;340:1439.
 
9. Chertin B, Spitz IM, Lindenberg T, et al. An implant releasing the gonadotropin releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. J Urol 2000;163:838–844.
 
10. Schlegel PN; Histrelin Study Group. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. J Urol 2006;175:1353–1358.